383185-93-1

Basic information

• Product Name: Cyclohexanamine, 1,3-dimethyl-, (1R,3R)-rel- (9CI)
• Synonyms: Cyclohexanamine, 1,3-dimethyl-, (1R,3R)-rel- (9CI)
• CAS NO: 383185-93-1
• Molecular Formula: C8H17N
• Molecular Weight: 127.22728
• Product Categories: AMINEPRIMARY
• Mol File: 383185-93-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclohexanamine, 1,3-dimethyl-, (1R,3R)-rel- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanamine, 1,3-dimethyl-, (1R,3R)-rel- (9CI)(383185-93-1)
• EPA Substance Registry System: Cyclohexanamine, 1,3-dimethyl-, (1R,3R)-rel- (9CI)(383185-93-1)

Safety Data

• Hazardous Substances Data: 383185-93-1(Hazardous Substances Data)

Upstream product

• 638-04-0 1,3-dimethylcyclohexane 
• 55539-04-3 1,3-dimethylcyclohexanol 
• 101252-17-9 1,3-dimethyl-1-nitro-cyclohexane 

Relevant articles and documents

Novel treatment for alzheimer's disease

The present invention concerns a new pharmaceutical composition comprising an antagonist and a co-agonist of the N-methyl-D-aspartate-type glutamate receptor (NMDAR). The inventors found that the co-administration of these two compounds effectively inhibits production of amyloide-β peptide. In patient's suffering from Alzheimer's disease, these peptides are deposited in the extracellular matrix forming neuritic "plaques". Therefore, the present inventors identified a new possibility for prophylaxis and/or treatment of Alzheimer's disease by stopping the continued formation of neuropathological extracellular deposits.

METHODS OF TREATING CNS DISORDERS

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors

The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

1-Amino-alkylcyclohexanes as trypanocidal agents

Certain 1-aminoalkylcyclohexanes are anti-trypanosomiasis agents and trypanocides. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating trypanosomiasis therewith.

Synthesis and structure-affinity relationships of 1,3,5-alkylsubstituted cyclohexylamines binding at NMDA receptor PCP site

A series of 1,3,5-alkylsubstituted cyclohexylamines 2 were synthesized as ligands for the N-methyl-D-aspartate (NMDA) receptor phencyclidine (PCP) binding site. Pure diastereomers with defined configuration of amino group 2- ax and 2-eq were obtained. The optimal size of 1,3,5-substituents was determined for cyclohexylamines 2 with an equatorial amino group in the lowest energy conformation using Hansch analysis. According to the data, the lipophilic part of cyclohexylamines 2 does not discriminate between hydrophobic regions of the PCP binding site but rather recognizes this site as a whole lipophilic pocket. (C) 2000 Editions scientifiques et medicales Elsevier SAS.